Natural and Synthetic Drugs Approached for the Treatment of Recurrent Aphthous Stomatitis Over the Last Decade

Abstract

Recurrent aphthous stomatitis (RAS) refers to a sore and frequently recurring inflammation of the oral tissues, distinguished by the presence of small ulcers that cause significant discomfort and cannot be attributed to any underlying disease. Different treatments have been used for RAS. This review aims to provide a comprehensive overview of the treatment options over the past decade for recurrent aphthous stomatitis (RAS), encompassing both natural and synthetic treatments. It will utilize clinical efficacy studies conducted in vivo and in vitro, along with a focus on the pharmaceutical approach through advancements in drug delivery development. We conducted a thorough literature search from 2013 to 2023 in prominent databases such as PubMed, Scopus, and Cochrane, utilizing appropriate keywords of recurrent aphthous stomatitis, and treatment. A total of 53 clinical trials with 3022 patients were included, with 35 using natural materials in their research and a total of 16 articles discussing RAS treatment using synthetic materials. All the clinical trials showed that natural and synthetic medicines seemed to benefit RAS patients by reducing pain score, ulcer size, and number of ulcers and shortening the healing duration.

Introduction

RAS is an oral mucosa disease characterized by recurrent, painful, single or multiple well-demarcated ulcerations with peripheral red halo where healing occurs with or without scarring.1 In the adult population, 60–85% of patients experience their first ulceration before age thirty. Although the primary causes of RAS remain unknown, certain factors have been identified as triggers for RAS outbreaks, including mental stress, trauma, lack of sleep, iron and folic acid deficiencies, menstruation, anemia, and changes in women’s sex hormones.2,3

With a 39% frequency, children are more likely to experience it.4 The prevalence rises with the female gender and a higher socioeconomic level and falls with age.5 Numerous perspectives have proposed that the oral microbiota could be the cause of RAS. Among the possibly significant components of the core microbiota responsible for this condition are Streptococcus, Helicobacter pylori, CMV (Cytomegalovirus), and a host of other unknown microorganisms.6 The presence of ulcers as a significant phenotype in systemic illnesses such as Crohn’s disease, Behçet’s illness, herpes stomatitis, and ulcerative colitis further compounds the difficulty in determining the etiologic cause.7 Stress may contribute to the likelihood of developing RAS; hence, it is crucial to address stress management in patients as a means of controlling its recurrence.8

Numerous therapies for RAS have been studied, such as topical steroids, local anesthetics, topical antibiotics, antiseptics, and analgesic/anti-inflammatory medications. Not every patient will respond well to topical therapies, despite the fact that they can be useful.9 Several systemic drugs have been investigated to treat RAS, including colchicine, thalidomide, dapsone, and corticosteroid.10 The current therapeutic options can only lessen the frequency or severity of the lesions. In most cases, the primary goal of RAS treatment is to achieve pain reduction (Visual Analog Scale Score),11 decrease in ulcer size, decrease in ulcer count, and acceleration of ulcer healing duration.12

Herbal supplements and natural items have been used for a long time and are recommended as an alternative to systemic pharmaceuticals due to their potential side effects.13,14 For them to serve as a resource and be considered while developing a treatment for RAS, this literature review addresses the natural and synthetic drug-based therapies for RAS that have been demonstrated, as well as the results of their potential.

Methods

We searched journals with the keywords “Recurrent Aphthous Stomatitis”, and “Treatment”, in 3 journal sources: PubMed, Scopus, and Cochrane. This narrative review was prepared based on studies related to the implementation of natural or synthetic products for “Recurrent Aphthous Stomatitis” AND “Treatment”. The authors use all original research and clinical reports published from 2013 to September 2023 regarding the use of treatment in recurrent aphthous stomatitis. The authors exclude irrelevant articles, which are the results of clinical research, but the results do not evaluate the effect on the health of research subjects, RAS treatment with laser or other physical intervention, research articles that do not clearly state the interventions, and other sources such as book chapters, article abstracts only, conference reports, reviews, posters, discussion results, and articles that only contain research designs. Authors C.V. and G.N.I. examined all the articles identified for inclusion. The authors later discussed the findings to reach a consensus. The procedure for selecting research articles is shown in Figure 1.

Figure 1.

The Procedure for selecting research articles.

Result

Numerous treatment methods have been reported to treat RAS. Natural and synthetic treatments are the most frequently reported among the various treatments. Other strategies involve physical interventions such as diode laser, Er, Cr:YSGG laser irradiation, and low laser therapy, to name a few.15–17 According to the results obtained from journal sources, treatment for RAS mainly uses topical medication in the form of gels, patches, ointments, and mouthwash.18 However, there are also therapies using oral drugs that work systemically. Data and explanations regarding natural and synthetic drug-based treatments used as RAS treatments are shown in Tables 1 and 2. The positive overall effect showed that the test materials produced a better outcome than the comparator or control material, as evidenced by the Negative overall impact, which indicates that the comparator or control materials outperformed the test materials, and not significant overall effect indicates that the materials indicated a better outcome with no significant difference with the comparator material.

Table 1.

Natural Materials

No.	Materials	Activity	Form	Dosage	Comparator	Subjects	Study Design	Overall Effect (Compared with Comparator)				Source
								Pain Reduction	Size of Ulcer	Number of Ulcer	Duration of Healing
1.	Rhus Coriaria	Analgesic, Anti-Inflammatory	Pill	Topical application, TID	Triamcinolone acetonide	22	Two-arm, single-blind, RCT	Not Significant	Not Significant	N/A	N/A	Lavaee et al (2022), Iran19
2.	Curcumin	Antioxidant, anti-inflammatory, disinfectant	Nanomicelle Gel	Topical application, TID	Curcumin gel	48	Double-blind, RCT	Positive	Positive	N/A	N/A	Bakhshi et al (2022), Iran20
			Gel	Topical application, TID	Triamcinolone acetonide	60	Double-blind, RCT	Negative	Negative	N/A	Negative	Raman et al (2020), India21
			Gel	Topical application, TID	Triamcinolone acetonide	60	Double-blind, RCT	Not Significant	Not Significant	Not Significant	Not Significant	Deshmukh et al (2014), India22
3.	Chitosan	Antibacterial, anti-inflammatory, wound-healing, hemostatic, immunomodulatory effects	Mucoadhesive film	Topical application, BID	Polyvinyl alcohol	72	Double-blind, RCT	Not Significant	Positive	N/A	N/A	Shao et al (2020), China23
			Mouthwash	5 cc oral application, TID	Triamcinolone acetonide	20	Double-blind, RCT	Not Significant	Not Significant	N/A	Not Significant	Rahmani et al (2018), Iran24
4.	Sage Extract	Anti-inflammatory, Antioxidant	Gel	Topical application, TID	Triamcinolone acetonide	60	Double-blind, RCT	Positive	N/A	N/A	Negative	Abbasi et al (2023), Iran25
5.	Lactobacillus acidophilus	Immunomodulatory effect	Lozenges	Oral application, BID	Choline salicylate	120	Double-blind, RCT	Positive	Not Significant	N/A	N/A	Aggour et al (2020), Egypt26
6.	Cinnamaldehyde	Anti-inflammatory	Mucoadhesive Patch	Topical application, BID	Placebo	44	Double-blind, RCT	Positive	Positive	N/A	N/A	Molania et al (2022) Iran27
7.	Omega-3	Anti-inflammatory	Capsule	Oral application, TID	Placebo	50	Double-blind, RCT	Positive	Positive	N/A	N/A	Nosrathezi et al (2016), Iran28
						40		Positive	Positive	Positive	Positive	Hadian et al (2021), Iran29
						50		Positive	N/A	Positive	Positive	Khouli et al (2014), Egypt30
8.	Non-aromatic very rich in steranes (NAVS) Napthalan	Immunomodulator effect	Adhesive paste	Topical application, TID	Betamethasone	24	Double-blind, RCT	Not Significant	Not Significant	Not Significant	N/A	Rogulj et al (2021), Croatia31
9.	Citrus essential oil	Antiulcerogenic, antibacterial	Mucoadhesive patch	Topical application, QD	N/A	37	Prospective, consecutive-group, before-after trial	Positive	N/A	N/A	N/A	Kürklü-Gürleyen, E et al, (2016), Turkey32
10.	Propolis Extract	Anti-inflammatory, antimicrobial, antioxidant, immuno-stimulant and wound healing activities	Adhesive buccal film	Topical application, BID	Placebo	24	Double-blind, RCT	Positive	Positive	N/A	Positive	Arafa et al (2018), Egypt33
11.	Pomegranate (Punica granatum var. pleniflora)	Antibacterial, anti-inflammatory, antifungal	Mouthwash	Oral application, QID	No treatment	210	Double-blind, RCT	Positive	Positive	N/A	N/A	Gavanji et al (2014), Iran34
			Gel	Topical application, BID	Placebo	56	Double-blind, RCT	Positive	Positive	Positive	Positive	Darakhshan et al (2019), Iran35
			Gel	Topical application, TID	Placebo	40	Double-blind, RCT	Positive	N/A	N/A	Positive	Tavangar et al (2013), Iran36
			Gel	Topical application, TID	Triamcinolone acetonide	60	Double-blind, RCT	Negative	Positive	N/A	Positive	Tavangar et al (2019), Iran37
12.	Honey	Wound-healing, antimicrobial	Not mentioned	N/A	Triamcinolone acetonide	94	Double-blind, RCT	Positive	Positive	N/A	Positive	El-Haddad et al (2014), Saudi Arabia38
13.	Ageratina pichinchensis	Wound-healing	Extract liquid	Oral application, TID	Triamcinolone acetonide	56	Double-blind, RCT	Positive	N/A	N/A	Positive	Romero-Cerecero et al (2015), Argentina39
14.	Cannabidiol	Analgesic, anti-inflammatory	Patch	Topical application, TID	Triamcinolone acetonide	50	Double-blind, RCT	Not Significant	Negative	N/A	N/A	Umpreecha et al (2023), Thailand40
15.	Lactobacillus reuteri	Immunomodulatory effect	Lozenges	Oral application, BID	Placebo	20	Double-blind, RCT	Not Significant	Not Significant	Not Significant	N/A	Pedersen et al (2019), Denmark41
16.	Tobacco (Nicotiana tabacum)	anti-aphthous	Mouthwash	Oral application, TID	Placebo	54	Double-blind, RCT	Positive	Positive	N/A	N/A	Vaziri et al (2016), Iran42
17.	Alum	Wound-healing	Patch	Topical application, TID	Placebo	50	Double-blind, RCT	Positive	Positive	N/A	Positive	Rafieian et al (2016), Iran43
18.	Gambier extract (Uncaria gambier)	Antibacterial, anti-inflammatory, antiseptic, antioxidant	Ointment	Topical application, TID	Placebo	30	Double-blind, RCT	Positive	Positive	N/A	Positive	Dewi et al (2020), Indonesia44
19.	Ginger rhizome (Zingiber officinalis)	Anti-inflammatory, antioxidant, analgesic and antiseptic	Membrane piece	Topical application, BID	Placebo	49	Double-blind, RCT	Positive	N/A	N/A	Positive	Qian Du et al (2018), China45
			Mucoadhesive patch	Topical application, BID	Placebo	15	Double-blind, RCT	Positive	Positive	N/A	N/A	Haghpanah et al (2014), Iran46
20.	Aloe vera	Analgesic, wound-healing	Gel	Topical application, TID	Amlexanox	60	Double-blind, RCT	Positive	Positive	N/A	N/A	Yousef et al (2022), Syria47
			Gel	Topical application, QID	Placebo	90	Double-blind, RCT	Positive	Positive	N/A	N/A	Mansour et al (2014), Egypt48
21.	Virgin coconut oil	Antioxidant	Oil	Topical application, BID	Triamcinolone acetonide	20	Double-blind, RCT	Not Significant	Not Significant	N/A	N/A	Halim et al (2014), Malaysia49
22.	Berberine gelatin	Anti-inflammatory, antimicrobial	Gelatin	Topical application, BID	Placebo	84	Double-blind, RCT	Positive	Positive	N/A	N/A	Jiang et al (2013), China50
23.	Camel whey protein	Antioxidant, antiinflammatory, antibacterial	Gel	Topical application, TID	Placebo	40	Double-blind, RCT	Not Significant	N/A	N/A	Positive	Elamrousy et al (2021), Egypt51
24.	Fenugreek seed (Trigonella foenum graecum L.)	Anti-inflammatory, analgesic, immunomodulator	Mouthwash	Topical application, TID	Dexamethasone	60	Double-blind, RCT	Positive	Positive	N/A	N/A	Ansari et al (2021), Iran52
25.	Licorice extract 5%	Anti-inflammatory	Bioadhesive paste	Topical application, QID	Diphenhydramine	60	Double-blind, RCT	Positive	N/A	N/A	N/A	Raeesi et al (2015), Iran53
26.	Chamomile (Matricia chamomilla)	Anti-inflammatory, antibacterial, analgesic	Tincture	Topical application, TID	Placebo	36	Double-blind, RCT	Positive	N/A	Positive	N/A	Seyyedi et al (2014), Iran54
			Orabase	Topical application, QID	Triamcinolone acetonide	45		Negative	Negative	N/A	N/A	Tadbir et al (2015), Iran55

Table 2.

Synthetic Materials

No.	Materials	Activity	Form	Dosage	Comparator	Subjects	Study Design	Overall Effect (Compared with Comparator)				Source
								VAS pain score	Size of Ulcer	Number of Ulcer	Duration of Healing
1.	Zinc Sulfate	Anti-inflammatory and wound-healing	Mucoadhesive paste	Topical application, TID	Placebo	55	Double blind, RCT	Positive	Positive	N/A	N/A	Ghorbani et al (2020), Iran56
			Tablet	Oral application. QD	Placebo	52		N/A	N/A	Positive	Positive	Al-Oudah et al (2020), Iraq57
2.	Tetanus and diphtheria toxoid vaccine – Colchicine 1 mg	Immunomodulator	Tablet & injection	Oral application, QD Intramuscular injection, Single dose	Colchicine & Vitamin B6	66	Triple blind, RCT	Positive	Positive	N/A	Positive	Habibzadeh et al (2019), Iran58
3.	Levamisole 50 mg and Prednisolone 5 mg	Immunomodulating agent, anti-inflammatory	Tablet	Oral application, TID	Placebo	50	Single blind, RCT	Positive	Positive	Positive	Positive	Sharda et al (2014), India59
4.	Doxycycline hyclate 100 mg	Antimicrobial, prostaglandin inhibitor, leukocyte suppression	Tablet	Oral application, QD	Placebo	50	Single blind, RCT	Positive	N/A	N/A	Positive	Vijayabala et al (2013), India60
5.	Amlexanox 5%	Anti-inflammatory	Paste	Topical application, TID/QID	Triamcinolone acetonide	60	Single blind, RCT	Negative	Negative	N/A	Negative	Shrivastava et al (2020), India61
6.	Betamethasone sodium phosphate 500 mcg	Anti-inflammatory	Mouthwash	Oral application, QID	Colchicine 500 mcg	86	Prospective, parallel-group, RCT	Positive	Positive	Positive	Positive	Alsahaf et al (2023), UK62
7.	N-acetylcysteine (NAC) 200 mg	Antioxidant, anti-inflammatory, immune-modulatory, antimicrobial	Mouthwash	Oral application, QD	Chlorhexidine (CHX)	58	Double blind, RCT	Positive	Not Significant	N/A	Not Significant	Halboub et al (2021), Yemen63
			Mucoadhesive tablet	Oral application, TID	Placebo	49		Positive	Positive	N/A	N/A	Eslami et al (2023), Iran64
8.	Topical insulin-liposomal	Wound-healing	Gel	Oral application, QD	Placebo	80	Double blind, RCT	Positive	N/A	N/A	Positive	El-Wakeel et al (2018), Egypt65
9.	Thalidomide 100 mg	Anti-inflammatory	Tablet	Oral application, QD	Prednisolone 0.4/kg	51	Double blind, RCT	Positive	Positive	Positive	Positive	Zeng et al (2019), China66
10.	Ibuprofen, diphenhydramine, Aluminum Magnesium Sulfate (AlMgS)	Analgesic, anti-inflammatory	Gel	Topical application, TID	Diphenhydramine and Aluminum Magnesium Sulfate (AlMgS)	31	Double blind, RCT	Not Significant	N/A	N/A	N/A	Borhan-Mojabi et al (2014), Iran67
11.	Minocycline 0.5%	Antibacterial	Mouthwash	Oral application, QID	Minocycline 0.2%	14	Double blind, RCT	Positive	N/A	N/A	Positive	Yarom et al (2017), Israel68
12.	Triester Glycerol Oxide	Anti-inflammatory, Reduce moisture loss	Gel	Topical application, QID	Triamcinolone acetonide	160	Double blind, RCT	Positive	Positive	N/A	N/A	Ofluoglu et al (2017), Turkey69
13.	Rebamipide 100 mg	Gastroprotective agent	Tablet	Oral application, TID	Levamisole 50 mg	100	Double blind, RCT	Not Significant	Not Significant	N/A	N/A	Devi et al (2014), India70
14.	Penicillin	Antibiotic, anti-inflammatory	Powder	Topical application, QID	Placebo	50	Double blind, RCT	Positive	Positive	N/A	Positive	Owlia et al (2020), Iran71

Abbreviations: QD, Once a day; BID, Twice a day; TID, Thrice a day; QID, 4 times a day; RCT, Randomized Controlled Trial.

A total of 3072 RAS patients were studied in this review. The sample size ranged from 15 to 210 patients in each study. Twenty-one different types of formulations were used in the articles, such as pasta, tablet, injection, mouthwash, gel, nanomicelle gel, powder, pill, film, lozenges, patch, capsule, buccal film, liquid, ointment, membrane piece, oil, gelatin, orabase, and tincture. The experimental period ranged from 5 days to 12 months.

Natural Treatment

Natural treatment is a naturally occurring secondary metabolite with possible clinical activity that is taken from living things like fungi, bacteria, plants, and animals.72 It is remarked that natural treatments are excellent sources for creating and manufacturing anti-inflammatory, analgesic, antimicrobial, and immunomodulator agents.73 Medicinal plants and natural remedies have long been conventionally used for various pharmacological uses.74

Numerous varieties of natural substances are employed in the research article that has been compiled. Each of these materials possesses distinct components and activities in managing Recurrent Aphthous Stomatitis (RAS). Typically, medications for RAS treatment are formulated in topical forms, including gels, patches, pastes, or mouthwash.18 This formulation is selected due to its capacity to endure in the oral cavity for an extended period, offering ulcer protection to mitigate deterioration and facilitating a swifter wound healing process.75

The entire study incorporated pain reduction as one of its outcome measures. Out of the 37 studies, 25 demonstrated that natural substances yielded superior therapeutic effects compared to the control materials. Pain assessment was conducted using the Visual Analog Scale (VAS) score, where a score of 1 signified minimal pain, and a score of 10 indicated maximum pain.76 Three studies, however, reported negative results or lower therapeutic effects compared to the comparator. The remaining 9 articles indicated better therapeutic effects than the comparator, although the differences were not statistically significant.

The reduction in ulcer size represented the second most frequently measured outcome in the trials. Out of 28 articles reporting on ulcer size reduction, 18 trials yielded positive results, 7 articles showed not statistically significant results, and 3 articles reported negative outcomes compared to the reference materials. Only 7 articles assessed the difference in the number of ulcers in the trials, with 3 showing results that were not statistically significant and 4 articles demonstrating a positive effect for RAS compared to the control materials. As for the reduction in healing duration, it was evaluated in 16 articles, with 12 reporting positive results and 2 articles each indicating results that were not statistically significant and negative compared to the control.

Synthetic-Based Treatment

Synthetic pharmaceuticals are formulated to address symptoms associated with specific diseases based on the scientific understanding of pathology.77 Synthetic drugs are pharmaceuticals derived from synthetic compounds and are typically prescribed by medical professionals to treat specific diseases.78 These synthetic medications represent a modern approach, often synthesized from artificial or naturally occurring substances that have undergone contemporary processing techniques.79

Therapeutic strategies for RAS primarily focus on alleviating pain and expediting wound healing.8 The management of minor aphthous ulcers involves supportive care, such as topical analgesics and protective bio-adhesive agents, while topical corticosteroids have been employed for both major and minor RAS ulcers.80 However, the frequent use of corticosteroids is often limited due to topical side effects and the risk of systemic absorption, including oral candidiasis, mucosal atrophy, susceptibility to infections, and gastrointestinal complications.81

There are 16 articles discussing the use of synthetic drugs in the management of RAS. Fifteen of these articles evaluate the effects of drug utilization on pain control, with 12 articles reporting positive outcomes, 1 article yielding negative results, and 3 articles indicating superior effects, albeit with non-significant differences.

Discussion

RAS is an oral mucosa disease characterized by recurrent, painful, single or multiple well-demarcated ulcerations with peripheral red halo where healing occurs with or without scarring.1 In the adult population, 60–85% of patients experience their first ulceration before age thirty.7 Although the primary causes of RAS remain unknown, certain factors have been identified as triggers for RAS outbreaks, including mental stress, trauma, lack of sleep, iron and folic acid deficiencies, menstruation, anemia, and changes in women’s sex hormones.2,3 The current therapeutic options can only lessen the frequency or severity of the lesions. In most cases, the primary goal of RAS treatment is to achieve pain reduction, decrease in ulcer size, decrease in ulcer count, and acceleration of ulcer healing duration.12

Various medications, whether derived from natural or synthetic sources, are employed as therapies for RAS, each with diverse mechanisms of action, including anti-inflammatory, antioxidant, immunomodulatory, analgesic, wound healing, antiulcer, antibacterial, antiviral, and antibiotic effects as depicted in Figure 2.73

Figure 2.

Mechanism of action for pharmacological active agents in RAS therapy. Created with Biorender.com.

Immune alterations are among the factors that contribute to the development of RAS. It starts with antigen secretion on keratinocytes that activates T lymphocytes, causing TNF-α secretion and leukocyte chemotaxis. Studies have demonstrated a 2–5-fold increase in the secretion of TNF-α in the saliva of individuals suffering from RAS.9 Therefore, anti-inflammatory agents are essential to cure RAS, such as thalidomide, which speeds up messenger RNA degradation to reduce TNF-α activity, and pentoxifylline, which inhibits TNF-α production.82 Another example is chitosan, which can suppress TNF-α production and inhibit cytokine synthesis. These actions trigger re-epithelialization and contribute to the rejuvenation of the mucous layer.83

The treatment of choice for RAS often includes natural immunomodulatory agents like Lactobacillus acidophilus and Lactobacillus reuteri and synthetic options like Levamisole. These drugs regulate both cellular and humoral immunity in individuals with RAS.41,59 Furthermore, levamisole exerts effects on T suppressor cells in vitro. Suppressing specific T-cell responses can result in immunosuppression, which is advantageous in managing RAS. This drug’s mechanism of action helps normalize the CD4+/CD8+ cell ratio and enhances IgA and IgM levels.59

Antioxidants also have a crucial role in the treatment of RAS. This condition can arise due to an elevated level of reactive oxygen species (ROS) that suppresses the activity of the immune system and induces cellular damage.84 Sage extract, a natural antioxidant, has been employed as a treatment for RAS. The phenolic and flavonoid compounds present in sage extract can enhance blood oxygen levels and protect the body against oxidative stress and free radicals that can cause cell damage, thus protecting against various types of ulcers.85 N-acetylcysteine (NAC), recognized for its potent antioxidant properties, is utilized as a therapy for RAS. In clinical scenarios characterized by glutathione deficiency and/or oxidative stress, the use of NAC has demonstrated effectiveness.86

The clinical presentation of RAS involves inflammation in the oral mucosa, manifesting as yellowish-white ulcers with clear boundaries and surrounded by an erythematous halo.87 Hence, substances with antiulcerogenic properties represent a viable therapeutic approach for RAS. Limonene, the primary component in citrus essential oil, exhibits antiulcerogenic activity.88 The antiulcerogenic effect of limonene acts as an immunomodulatory agent for oral aphthous ulcers.32 The mechanism of these properties is attributed to its capacity to enhance mucus secretion, heat shock protein-70, vasoactive intestinal peptide, and prostaglandin E2.88 In addition, rebamipide, which has activity as a gastro protective agent, is also recommended as RAS therapy, especially to improve ulcer conditions. It works by diminishing oxygen radicals, enhancing blood flow, and promoting the production of protective prostaglandins in the ulcerated mucosa, thereby expediting the healing process.89

In the management of RAS, supportive treatment is often advised, which aims to reduce pain, accelerate healing, and prevent recurrence.90 To reduce pain, it is essential to utilize medications with analgesic properties. Diphenhydramine and aluminum magnesium simethicone (AlMgS) syrup are often prescribed as an analgesic mouthwash to mitigate various symptoms of oral ulcers, including aphthous ulcers. Ibuprofen is a potent non-steroidal anti-inflammatory drug (NSAID) with significant anti-inflammatory capabilities and is frequently recommended in dental care.67 Moreover, natural substances like cannabidiol, aloe vera, fenugreek seed, and chamomile are known to possess analgesic properties and can be employed as therapeutic options for RAS.40,47,52,54

Supportive treatment to accelerate wound healing is important, and substances like alum and Ageratina pichinchensis can be valuable. Alum, for instance, induces tissue contraction, which reduces mucous membrane inflammation and accelerates wound healing.91 Ageratina pichinchensis also exhibits wound healing properties. In vitro studies have shown that the compound 7-O-(β-D-glucopyranosyl) galactin, found in Ageratina pichinchensis, can stimulate the proliferation of normal human skin cells (HFS-30), thereby promoting the acceleration of wound healing.39 Other natural compounds that significantly accelerate wound healing are propolis, honey, and aloe vera.33,38,47 Additionally, a synthetic compound known as topical insulin-liposomal has demonstrated its potential in this regard. Insulin, when applied topically, can enhance the healing process by accelerating re-epithelialization, promoting angiogenesis, and stimulating the secretion of extracellular matrix components in keratinocytes, endothelial cells, and fibroblasts.65,92

The antibacterial properties are also crucial for treating RAS because open sores on mucosal tissues make it easy for bacteria to colonize, especially Gram-positive bacteria, which can slow down the healing process.93 Bacterial infections disrupt the regeneration of the oral mucosa. Eradicating microbes within the oral cavity supports the normal wound healing process.94 The presence of catechins in gambier extract possesses the ability to reduce bacterial populations in oral ulcers. Catechins modify membrane fluidity, resulting in a loss of membrane integrity and, ultimately, bacterial cell death.95 Other studies have also indicated the effectiveness of gambier extract in reducing the levels of Streptococcus mutans in saliva.44 By maintaining a sterile wound environment, gambier extract expedites the wound healing process by promoting angiogenic responses.96

From the analysis of a total of 53 clinical trials conducted by the authors in the last 10 years, natural-based medicines have shown significant improvement in patients’ symptoms, including the reduction of pain scores, ulcer size, the number of ulcers, and a decrease in ulcer healing duration. However, when compared with the control group, natural-based medicines provided better therapeutic effects compared to negative control or placebo but did not demonstrate significantly different or superior therapeutic effects compared to positive control or triamcinolone acetonide.

The drug delivery system also plays a crucial role in influencing the effectiveness of RAS therapy.97 Typically, medications intended for RAS treatment are formulated in topical forms, such as gels, patches, pastes, or mouthwash.9 This choice of the formulation is made because it can persist in the oral cavity for an extended period, providing protection against ulcer deterioration and facilitating a more rapid wound healing process.98,99 For instance, in the case of curcumin nanomicelle gel, it has shown better therapeutic outcomes than curcumin gel.20 This is because nanomicelle gel does not readily dissolve in saliva, making it highly suitable for the physiological conditions of the oral cavity and facilitating easy absorption by the mucosa.100 Furthermore, the development of drug delivery systems for RAS is an ongoing endeavor, encompassing research conducted in both in vitro and in silico settings. These developments include muco-adhesive sponges containing tenoxicam and miconazole nitrate,101 hydrogel formulations with alpha mangostin,102 adhesive buccal films comprising alginate and ambroxol,103 prednisolone,104 and benzydamine hydrochloride,105 as well as mucoadhesive films containing betamethasone valerate,106 and clobetasol propionate.107

The trial duration also shows a rather significant difference, with synthetic-based drugs having trial periods ranging from 3 days to 12 months. Topical and systemic corticosteroids, antibiotics, and analgesics are highly recommended for RAS patients.80 However, extended treatment periods and frequent exposure to these medications can lead to fungal infections and drug resistance, which can subsequently result in more severe side effects or even life-threatening complications.75 Therefore, the long-term use of these medications for RAS management should be avoided.108

Finding effective treatment for oral disease is among the most critical challenges of oral medicine. Consequently, there is a demand for therapy that can be effectively administered to the oral mucosa, withstand the washout effect of saliva, maintain a good safety profile, and minimize adverse side effects.109 Research in RAS therapy is an ongoing endeavor encompassing various stages of development, starting with drug formulation, pre-clinical testing, and clinical trials. An example of such research is the study conducted by Milanda et al, in which the compound alpha mangostin was utilized as a hydrogel film formulation based on chitosan alginate. This formulation demonstrated in vivo efficacy in the context of RAS therapy in white mice. The efficacy was indicated by the swiftest healing process, as determined through slope calculations.110

In summary, current data indicate a favorable benefit from both synthetic and natural remedies for the treatment of recurrent acute stomatitis (RAS). These remedies have demonstrated effectiveness in reducing pain, the number of ulcers, ulcer size, and healing duration. Natural remedies are recognized for their therapeutic benefits in RAS treatment but have yet to surpass the effectiveness of corticosteroid therapy. Conversely, the use of synthetic remedies, such as corticosteroids, tends to be of longer duration and raises concerns regarding potential side effects. The development of RAS therapy, including active ingredients, formulations, and delivery systems, must continue to be pursued in order to obtain effective, safe, and minimally side-effect-inducing treatments from both natural and synthetic sources.

Conclusion

The utilization of natural and synthetic medicinal approaches for the treatment of recurrent aphthous stomatitis (RAS) has exhibited considerable success in enhancing the well-being of patients, as evidenced by the reduction in pain, ulcer size, ulcer count, and the duration required for complete healing. Nevertheless, natural-based medicines necessitate further investigation and research to establish their therapeutic effectiveness equivalent to or surpassing that of corticosteroids, intending to potentially be integrated as a standard treatment modality for RAS. The progression of RAS therapy, encompassing the exploration of active constituents, formulations, and delivery systems, must persist in attaining effective and safe treatments while inducing minimal side effects originating from both natural and synthetic sources.

Funding Statement

Kedaireka Matching Fund, Ministry of Education and Culture, Republic of Indonesia (20/E1/PPK/KS.03.00/2023).

Abbreviations

RAS, Recurrent Aphthous Stomatitis; CMV, Cytomegalovirus; NAC, N-Acetylcysteine; VAS, Visual Analog Scale; AlMgS, Aluminum Magnesium Simethicone; NSAID, Non-steroidal Anti-inflammatory Drug; RCT, Randomized Controlled Trial; QD, Once a day; BID, Twice a day; TID, Thrice a day; QID, 4 times a day.

Disclosure

The authors report no conflicts of interest in this work.